Virtual ACC 2020 | ISCHEMIA-CKD: Invasive Strategy vs. Medical Treatment in Higher Risk Patients

This pre-specified protocol originally included 777 patients with chronic kidney failure. These patients are a special population of higher risk where we might be able to see the advantage of a more aggressive initial strategy.

Death or MI rate (combined primary end point) resulted 36.4% for the invasive strategy vs. 36.7% for the initially conservative strategy with optimal medical treatment (HR 1.01; CI 95% 0.79-1.29). 

Secondary end points such as death rate considered separately, non-fatal MI, hospitalization due to unstable angina, cardiac failure or cardiac arrest also resulted practically identical with 38.5% vs 39.7%, respectively (HR 1.01; CI 95% 0.79 to 1.29).

Stroke rate increased with the invasive strategy (HR 3.76; 95% CI 1.52-9.32) as well as risk of dialysis HR (1.48; CI 95% 1.04-2.11).


Read also: Virtual ACC 2020 | Controversial Trial ISCHEMIA Finally in NEJM.


And it this weren’t enough, patients with chronic kidney failure didn’t even show symptom improvement after revascularization. 

ischemia-ckd

Original Title: Management of coronary disease in patients with advanced kidney disease.

Reference: Bangalore S et al. N Engl J Med. 2020; Epub ahead of print y presentado en forma virtual en el ACC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...